Cargando…

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC

PURPOSE: The landscape of HER2+ metastatic breast cancer (mBC) treatment is changing due to the availability of new anti-HER2 drugs. The purpose of this study was to assess the current treatment patterns and sequences used in HER2+ mBC in the real-world setting. Secondary objectives were to describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomer, R., Hall, P., Szkultecka-Debek, M., Bondi, R. C., Flinois, A., Auziere, S., Le Cléac’h, J. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847072/
https://www.ncbi.nlm.nih.gov/pubmed/29170976
http://dx.doi.org/10.1007/s10549-017-4567-z
_version_ 1783305682955534336
author Colomer, R.
Hall, P.
Szkultecka-Debek, M.
Bondi, R. C.
Flinois, A.
Auziere, S.
Le Cléac’h, J. Y.
author_facet Colomer, R.
Hall, P.
Szkultecka-Debek, M.
Bondi, R. C.
Flinois, A.
Auziere, S.
Le Cléac’h, J. Y.
author_sort Colomer, R.
collection PubMed
description PURPOSE: The landscape of HER2+ metastatic breast cancer (mBC) treatment is changing due to the availability of new anti-HER2 drugs. The purpose of this study was to assess the current treatment patterns and sequences used in HER2+ mBC in the real-world setting. Secondary objectives were to describe the factors that influence the decision to prescribe a first and second-line antitumour treatment. METHODS: Retrospective chart review of 3068 cases in Spain, Italy, the Netherlands and the UK. RESULTS: First and second-line treatments and regimens are consistent with the clinical guidelines, especially for recently initiated treatments. Age and performance status (PS) of patients impact treatment patterns: younger patients received more innovative treatments than elderly patients. In addition, while most patients received a first antitumor treatment, the rate of patients who continue to subsequent lines of therapy is low (55% transitioning from 1st to 2nd line; 58% from 2nd to 3rd line). Age and PS are key factors in the decision to prescribe further antitumor treatment. CONCLUSION: Fewer HER2+ mBC patients than expected receive a second and third line therapy. Guidelines should make specific recommendations for older patients or those with a poor PS.
format Online
Article
Text
id pubmed-5847072
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-58470722018-03-20 Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC Colomer, R. Hall, P. Szkultecka-Debek, M. Bondi, R. C. Flinois, A. Auziere, S. Le Cléac’h, J. Y. Breast Cancer Res Treat Epidemiology PURPOSE: The landscape of HER2+ metastatic breast cancer (mBC) treatment is changing due to the availability of new anti-HER2 drugs. The purpose of this study was to assess the current treatment patterns and sequences used in HER2+ mBC in the real-world setting. Secondary objectives were to describe the factors that influence the decision to prescribe a first and second-line antitumour treatment. METHODS: Retrospective chart review of 3068 cases in Spain, Italy, the Netherlands and the UK. RESULTS: First and second-line treatments and regimens are consistent with the clinical guidelines, especially for recently initiated treatments. Age and performance status (PS) of patients impact treatment patterns: younger patients received more innovative treatments than elderly patients. In addition, while most patients received a first antitumor treatment, the rate of patients who continue to subsequent lines of therapy is low (55% transitioning from 1st to 2nd line; 58% from 2nd to 3rd line). Age and PS are key factors in the decision to prescribe further antitumor treatment. CONCLUSION: Fewer HER2+ mBC patients than expected receive a second and third line therapy. Guidelines should make specific recommendations for older patients or those with a poor PS. Springer US 2017-11-23 2018 /pmc/articles/PMC5847072/ /pubmed/29170976 http://dx.doi.org/10.1007/s10549-017-4567-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Epidemiology
Colomer, R.
Hall, P.
Szkultecka-Debek, M.
Bondi, R. C.
Flinois, A.
Auziere, S.
Le Cléac’h, J. Y.
Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
title Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
title_full Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
title_fullStr Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
title_full_unstemmed Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
title_short Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
title_sort real-world treatment in patients with her2+ metastatic breast cancer: treatment decisions in her2+ mbc
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847072/
https://www.ncbi.nlm.nih.gov/pubmed/29170976
http://dx.doi.org/10.1007/s10549-017-4567-z
work_keys_str_mv AT colomerr realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc
AT hallp realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc
AT szkulteckadebekm realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc
AT bondirc realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc
AT flinoisa realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc
AT auzieres realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc
AT lecleachjy realworldtreatmentinpatientswithher2metastaticbreastcancertreatmentdecisionsinher2mbc